Posted by Thomas Dobrow on Dec 20th, 2024
HC Wainwright reiterated their buy rating on shares of Verastem (NASDAQ:VSTM – Free Report) in a research report released on Thursday morning,Benzinga reports. HC Wainwright currently has a $7.00 price objective on the biopharmaceutical...
More of this article »